Trade AURA anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
Aura Biosciences, Inc. (AURA) is trading at US$7.52, down 2.40% today as of Aug 28, 12:40 EDT. The company has a market capitalisation of US$808.9M. Over the past 52 weeks, AURA has traded between US$4.73 and US$9.54. On Syfe you can trade AURA with $0 commission and add it to your watchlist.
| Previous close | US$7.70 |
|---|---|
| Market cap | US$808.9M |
| 52-week range | US$4.73 – US$9.54 |
| Volume | 440.03K |
| Exchange | US |
Add to Watchlist
Set Price Alert
Aura Biosciences, Inc.
Aura Biosciences, Inc. is a clinical-stage oncology company, which engages in developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity. The firm's product candidate belzupacap sarotalocan (AU-011) is in Phase 2 development for the first line treatment of choroidal melanoma, a vision and life-threatening form of eye cancer where standard of care radioactive treatments leave patients with major vision loss and severe comorbidities. The was founded by Elisabet de los Pinos in 2007 and is headquartered in Boston, MA.
Year: 2021
Aura Biosciences Completes Enrollment in Phase 3 Trial of Belzupacap Sarotalocan for Early Choroidal Melanoma
Jun 1, 12:39 PM · MT Newswires
Aura Biosciences Prices $260 Million Stock Offering
May 4, 2:18 PM · MT Newswires
Top Premarket Decliners
Mar 9, 11:43 AM · MT Newswires
Aura Biosciences, Inc. (AURA) stock is trading at US$7.52, -2.40% from the previous close of US$7.70.
The market cap for Aura Biosciences, Inc. (AURA) stock is approximately US$808.9M.
The 52-week high for Aura Biosciences, Inc. (AURA) stock is US$9.54.
The 52-week low for Aura Biosciences, Inc. (AURA) stock is US$4.73.
Aura Biosciences, Inc. (AURA) does not currently pay a dividend.
Stay on top of AURA
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
